Aviptadil
Also known as: RLF-100, VIP sintético, Peptídeo Intestinal Vasoativo sintético
Molecular Identifiers
Molecular Formula
C147H237N43O43S
CAS Number
40077-57-4
PubChem CID
16132300Molecular Weight
3326.8 Da
Overview
Synthetic analog of vasoactive intestinal peptide (VIP), composed of 28 amino acids. Originally developed for respiratory and vascular conditions, it acts as a potent pulmonary vasodilator and anti-inflammatory agent. Extensively researched for lung protection and surfactant function regulation.
Aviptadil is a synthetic analog of vasoactive intestinal peptide (VIP), and its clinical interest is concentrated in the lungs: VPAC1/VPAC2 receptor agonism produces pulmonary vasodilation, anti-inflammatory modulation of the alveoli, stimulation of surfactant production by type II pneumocytes, and protection of the respiratory epithelium against apoptosis. It has been investigated in pulmonary arterial hypertension and in acute respiratory failure.
The peptide gained prominence during the COVID-19 pandemic, when it was tested (under the name RLF-100) as a treatment for severe ARDS; the program advanced through clinical trials but did not obtain drug approval. It currently remains an investigational compound, available in some countries through compassionate use. It has no registered indication with the FDA, EMA, or ANVISA. The very short half-life (1-2 minutes IV) explains the need for continuous infusion or multiple administrations, and intravenous use requires clinical supervision due to the risk of hypotension.
HSDAVFTDNYTRLRKQMAVKKYLNSILN His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn Half-life
~1-2 minutes (IV)
Administration Route
Intravenous or subcutaneous
Category
Specialized Research
Mechanism of Action
- Agonism of VIP VPAC1 and VPAC2 receptors
- Pulmonary and systemic vasodilation via cAMP increase
- Anti-inflammatory action in pulmonary alveoli with reduction of pro-inflammatory cytokines
- Stimulation of surfactant production by type II pneumocytes
- Inhibition of apoptosis in alveolar epithelial cells
- Modulation of the innate immune response in the lungs
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 50-150 mcg per administration (IV or subcutaneous) |
| Frequency | 1-3 times daily per protocol |
| Timing | Per clinical guidance |
| Duration | 4-8 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Hypotension
- Tachycardia
- Nausea
- Diarrhea
- Facial flushing
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water, sterile saline, and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C, use within 24 hours. Protect from light and moisture. Short half-life — use reconstituted solution promptly. |
Presentations & Preparation
Vials of Aviptadil found in the research market:
Reconstitution
- Diluent: Bacteriostatic water or sterile saline solution
- Volume: 1-2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved — never shake
- For IV use, dilute in saline solution per protocol
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 24 hours)
- Protect from direct light
- Do not freeze after reconstitution
- Use reconstituted solution as soon as possible
Scientific Studies
Published studies on Aviptadil.
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure
Youssef JG, Lavin P, Schoenfeld DA, Lee RA, Lenhardt R, Park DJ, et al.
Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate
Dinsmore WW, Gingell C, Hackett G, Kell P, Savage D, Oakes R, Frentz G
Related Peptides
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals
Dalargin
1-2 mg per injection (subcutaneous or intramuscular) · 1-2 times daily